- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05053672
ReOxy Therapy in the Rehabilitation of Chronic Low Back Pain Patients With Comorbidity
The Respiratory Therapy Method Based on Short-term Intermittent Exposures Hypoxia and Hyperoxia (ReOxy Therapy) in the Rehabilitation of Chronic Low Back Pain Patients With Cardiac or Pulmonary Comorbidities: a Randomized Controlled Trial
Study Overview
Detailed Description
This is a randomized, single-blinded, placebo-controlled trial, with chronic non-specific low back pain with multiple chronic conditions. Comorbidity constitutes a serious challenge for rehabilitative medicine - significantly reduces the patients' quality of life and restoration of the working capacity.
The objective of the present study will be to evaluate the effectiveness of the combined non-medicinal rehabilitation programe which include a course of ReOxy- therapy and conventional therapy back pain treatment.
90 patients will be randomly allocated to three treatment groups: experimental ("hypoxic group" - ReOxy therapy + conventional therapy back pain treatment), placebo ("sham hypoxic group"- sham- ReOxy therapy + conventional therapy back pain treatment) and control (only conventional therapy back pain treatment).
The clinical outcomes will be obtained at the completion of treatment (2 weeks) and at 1 month after randomization. The statistical analysis will follow the intention-to-treat principles and the between-group differences will be calculated by using mixed linear models.
The outcomes of interest are pain intensity, lumbar range of motion function, general physical and mental status.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation
- Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine, Dept. No. 9
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with non-specific chronic low back pain for at least 3 months;
- A pain intensity of at least 5 points measured by 0 -10 points pain rating scale;
- Co-morbidity - IHD and/or CHF and/or COPD and/or chronic bronchitis)
- Willing and able to consent, complete all assessment and study procedures;
Exclusion Criteria:
- Specific types of back pain (metastatic cancer or bone cancer or secondary cancers, vertebral fractures, spinal infection, active inflammatory disease);
- Low back surgery within past 3 months;
- Serious cardiovascular, cerebrovascular, neuromuscular and other systemic diseases or other diseases affecting physical activity;
- Any significant systemic illness or medical condition that could affect safety or compliance with study;
- Major active or chronic unstable psychiatric illness (e.g. depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year;
- Tumour disease except being successfully treated and off treatment with >2 years. Tumour disease except being successfully treated and off treatment with >2 years.
- Use of other investigational agents or interventions one month prior to entry and for the duration of the trial;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Conventional therapy back pain treatment
Participants randomized to сonventional therapy group will receive complex rehabilitation program including physical exercise, phonophoresis with hydrocortisone, lumbar region massage, acupuncture within 2 weeks.
|
|
|
Active Comparator: Conventional physiotherapy therapy back pain treatment + ReOxy-therapy
Participants randomized to Active Comparator group will receive complex rehabilitation program and 10 ReOxy-therapy sessions within 2 weeks (5 sessions per week).
|
ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session. The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min. During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control). |
|
Placebo Comparator: Conventional physiotherapy therapy + Sham ReOxy-therapy
Participants randomized to Placebo Comparator group will receive complex rehabilitation program and 10 sham ReOxy-therapy sessions within 2 weeks (5 sessions per week).
|
Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions.
Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve.
The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Back pain intensity will be measured by the Visual Analog Scale
Time Frame: Baseline, end of the 2-nd week
|
Visual analogue scale (VAS) is a simple and frequently used method for the assessment of variations in intensity of pain.
The VAS consists of a 10cm horizontal line with the words "no pain" and "worst pain" at the line's end.
VAS is a reliable and valid tool to reliable and valid tool to measure pain intensity measure pain intensity.
|
Baseline, end of the 2-nd week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Back pain intensity
Time Frame: Baseline and 1-month post randomization
|
Back pain intensity will be measured by the Visual Analog Scale Visual analogue scale (VAS) is a simple and frequently used method for the assessment of variations in intensity of pain.
The VAS consists of a 10cm horizontal line with the words "no pain" and "worst pain" at the line's end.
VAS is a reliable and valid tool to reliable and valid tool to measure pain intensity measure pain intensity.
|
Baseline and 1-month post randomization
|
|
Roland Disability Questionnaire (RDQ)
Time Frame: Baseline and 1-month post randomization
|
The Roland-Morris Questionnaire is a self-administered disability measure in which greater levels of disability are reflected by higher numbers on a 24-point scale
|
Baseline and 1-month post randomization
|
|
Lumbar Range of Motion
Time Frame: Baseline, end of the 2-nd week
|
Will be evaluated through the finger-to-floor test.
Participant try to reach the floor with his fingertip by bending forward in the same time knees are kept extended.
The distance between fingertips and floor are measured in centimetres by examiner.
|
Baseline, end of the 2-nd week
|
|
Change of lower back flexibility
Time Frame: Baseline, end of the 2-nd week
|
Will be evaluated through Schober test (positive/negative).
The examiner places one finger 5cm below the mark pproximately at the level of L5 and another finger at about 10cm above this mark.
The patient is then instructed to touch his toes.
If the increase in distance between the two fingers on the patients spine is less than 5cm then this is indicative of a limitation of lumbar flexion.
|
Baseline, end of the 2-nd week
|
|
6 min-walking test distance
Time Frame: Baseline, end of the 2-nd week
|
Change in walking distance in meters during a 6-min period over a corridor of 30m length
|
Baseline, end of the 2-nd week
|
|
Hospital Anxiety and Depression Scale, HADS
Time Frame: Baseline and 1-month post randomization
|
The Hospital Anxiety and Depression Scale (HADS) is a questionnaire, comprising fourteen questions. Each item on the questionnaire is scored from 0-3. The scale is devided into 2 parts: (1) anxiety (minimum score 0, maximum sore 21) and (2) depression (minimum score 0, maximum sore 21). Scoring : 0-7- normal, 8-10-borderling abnormal, 11-21-abnormal |
Baseline and 1-month post randomization
|
|
Bergen Insomnia Scale (BIS)
Time Frame: Baseline and 1-month post randomization
|
The BIS comprises six items that assesses symptoms of insomnia based on the insomnia criteria found in the Diagnostic and Statistical Manual of Mental Disorders-IV-TR (American Psychiatric Association).
Higher values indicate higher levels of insomnia severity.
|
Baseline and 1-month post randomization
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HR recovery after the 6-minute walk test
Time Frame: Baseline and end of the 2-nd week
|
HR recovery measured by sphygmomanometer after the 6-minute walk test
|
Baseline and end of the 2-nd week
|
|
SAD/DAD recovery after the 6-minute walk test
Time Frame: Baseline and end of the 2-nd week
|
SAD/DAD recovery measured by sphygmomanometer after the 6-minute walk test
|
Baseline and end of the 2-nd week
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nadezhda Lyamina, M.D., Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4 11052021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Back Pain
-
University of Kansas Medical CenterCompletedLower Back Pain | Low Back Pain | Low Back Pain, Mechanical | Low Back Pain, Recurrent | Low Back Pain, Postural | Postural Low Back Pain | Mechanical Low Back Pain | Low Back Ache | Recurrent Low Back Pain | Lower Back Pain Chronic | Low Back Pain, Posterior Compartment | Low BackacheUnited States
-
Istanbul UniversityIstinye UniversityCompletedLow Back Pain | Low Back Pain, Mechanical | Low Back Pain, Recurrent | Low Back Pain, PosturalTurkey
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
General Incorporated Foundation Ryukyuseimeisaiseikai...CompletedChronic Low Back Pain | Non-specific Low Back Pain | Low Back Pain (LBP)Japan
-
University School of Physical Education in WroclawCompletedLow Back Pain | Low Back Pain, Mechanical | Low Back Pain, PosturalPoland
-
Texas Woman's UniversityTexas Physical Therapy AssociationCompletedLow Back Pain | Chronic Low Back Pain | Subacute Low Back PainUnited States
-
University of ParmaKing's College London; Helmholtz Zentrum München; GENOS; Ip Research Consulting... and other collaboratorsUnknownChronic Low Back Pain | Acute Low Back PainUnited States, Australia, Belgium, Croatia, Italy, United Kingdom
-
Karolinska InstitutetCompletedChronic Low Back Pain | Recurrent Low Back Pain | Persistent Low Back PainSweden
-
Ache Laboratorios Farmaceuticos S.A.Unknown
Clinical Trials on ReOxy
-
I.M. Sechenov First Moscow State Medical UniversityCompletedSurgery | Valvular Heart Disease | Aortic Arch AneurysmRussian Federation
-
I.M. Sechenov First Moscow State Medical UniversityCompletedMetabolic Syndrome | Vascular Stiffness | Liver Fibroses | Trimethylamine N-oxyde | Toll-like ReceptorsRussian Federation